Nutlin-3a

Catalog No.S8059 Synonyms: (-)-Nutlin-3

Nutlin-3a Chemical Structure

Molecular Weight(MW): 581.49

Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.

Size Price Stock Quantity  
USD 197 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Protein expression of TP53 and p21 of ovarian cancer cell lines after treated with Nutlin-3a for 24, 48 and 72 hours at their corresponding IC50 as indicated. C, untreated control; *, cancer cell lines carrying TP53 mutation. Het, heterozygous TP53 mutation; hom, homozygous TP53 mutation.

    PLoS One, 2015, 10(8):e0135101.. Nutlin-3a purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Nutlin-3a, the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.
Targets
p53/MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro

Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM nutlin-3a led to >90% inhibition of NIH3T3 cells’ growth[1]. Nutlin-3a stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. Nutlin-3a effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. Nutlin-3a induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSzTWM2OD1yLk[xNlM4KM7:TR?= NUfwNpZDW0GQR1XS
H4 M2jpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzKTWM2OD1yLk[2Nlgh|ryP NG\DdIdUSU6JRWK=
PA-1 MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXPWopxUUN3ME2wMlg4ODl4IN88US=> NG\acYlUSU6JRWK=
NKM-1 NFLHc4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XhbGlEPTB;MT6wOFk{OSEQvF2= M17CcXNCVkeHUh?=
NEC8 NYDxZZdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwMkG1O|Ih|ryP NWnmT3pYW0GQR1XS
EoL-1-cell MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLyTWM2OD1zLkK2O|AyKM7:TR?= NVvHW3NHW0GQR1XS
K5 Ml:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwNEKwO|Ih|ryP NIC4SoFUSU6JRWK=
QIMR-WIL MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjnNpZ6UUN3ME2xMlYxQDV2IN88US=> NIDJVY1USU6JRWK=
MOLT-16 NFvzVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1SyO2lEPTB;MT63PFYxPCEQvF2= MWHTRW5ITVJ?
CHP-212 NHv0[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH0TWM2OD1zLkixN|Y6KM7:TR?= NXPxcWRjW0GQR1XS
CTB-1 NX7zb21wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[yNIxKSzVyPUKuNFIzPDZizszN NFLuO2tUSU6JRWK=
MOLT-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTNV29SUUN3ME2yMlMzQDV|IN88US=> NGDGcJBUSU6JRWK=
A101D NEfHUm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTjTWM2OD1{LkO1NFEh|ryP MnfqV2FPT0WU
DOHH-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPKTVVKSzVyPUKuOFIzPzlizszN MUfTRW5ITVJ?
ES4 NYrBUWFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPmXZRKSzVyPUKuOFMyPTVizszN M4i4VXNCVkeHUh?=
SW780 MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzCTWM2OD1{LkWwPFg{KM7:TR?= MWDTRW5ITVJ?
VA-ES-BJ MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHlR2I4UUN3ME2yMlU1OTFizszN M4n6TnNCVkeHUh?=
RPMI-8866 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTZZ2RKSzVyPUKuOVYzOTRizszN NFLqdJJUSU6JRWK=
ML-2 NF:1UGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJwNU[1O|Yh|ryP MorBV2FPT0WU
MSTO-211H NXLT[JA4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\rTWM2OD1{LkW3OFUyKM7:TR?= MkTxV2FPT0WU
JVM-3 NWHqNoNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTwTWM2OD1{LkW5N|I1KM7:TR?= NUfvZm5KW0GQR1XS
A3-KAW NVP4e40{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPM[4dHUUN3ME2yMlYyQDF6IN88US=> M2XQR3NCVkeHUh?=
DK-MG MnHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DTOmlEPTB;Mj62NlQ4OSEQvF2= Mk\HV2FPT0WU
LNCaP-Clone-FGC NIfzTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\UWVJRUUN3ME2yMlY1OzF6IN88US=> NW\5RVNvW0GQR1XS
HT-144 Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPhUYUyUUN3ME2yMlY1PTd5IN88US=> MYjTRW5ITVJ?
NB69 M2P4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDrO5ZFUUN3ME2yMlY2OzN2IN88US=> MoPhV2FPT0WU
A172 NUnTVHFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rZd2lEPTB;Mj62O|U5QCEQvF2= NH7rbYhUSU6JRWK=
RS4-11 NXLkUJNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TVRmlEPTB;Mj63NlQxPyEQvF2= M{jkV3NCVkeHUh?=
DU-4475 MkXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf6bldKSzVyPUKuO|k2ODJizszN M3[z[HNCVkeHUh?=
SJSA-1 M1jyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWCzU5lrUUN3ME2yMlgzPTV4IN88US=> MkXjV2FPT0WU
BV-173 NF;WdIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJwOES0N|kh|ryP MWnTRW5ITVJ?
U-2-OS M3G1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTJwOUGwO{DPxE1? NWTrNYdMW0GQR1XS
CHP-134 NGTPbZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHD[HZLUUN3ME2yMlk{QDh{IN88US=> M4XH[HNCVkeHUh?=
D-502MG MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwOUexOVQh|ryP NHrhbWNUSU6JRWK=
KS-1 NVjBfIxGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7Tfo9KSzVyPUOuNFE3OjNizszN MlvyV2FPT0WU
A204 Ml75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPIdopKSzVyPUOuNFU2QDhizszN NG[3eYNUSU6JRWK=
KGN MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTNwMEi0PVYh|ryP NWe3WmZGW0GQR1XS
NCI-H292 NGnsZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXKTWM2OD1|LkGyNFI5KM7:TR?= NGPpWFlUSU6JRWK=
CAKI-1 NYW0R4Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPYTWM2OD1|LkGyOlk1KM7:TR?= MXrTRW5ITVJ?
C2BBe1 M13yV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moe0TWM2OD1|LkG3NFI3KM7:TR?= NIK0N|BUSU6JRWK=
NB10 NEjrNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnsfIZKSzVyPUOuNlA6PjZizszN MYDTRW5ITVJ?
MHH-NB-11 NHrpXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXUTWM2OD1|LkK2PFI4KM7:TR?= MkjFV2FPT0WU
NCI-SNU-1 NHfmS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj4NGV{UUN3ME2zMlI4QDR|IN88US=> NVXheFNRW0GQR1XS
HCT-116 NWSyUHYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;yTWM2OD1|LkOwN|M2KM7:TR?= NFLKcVJUSU6JRWK=
G-401 NYDjSGdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTNwM{[zNlIh|ryP NET3OJpUSU6JRWK=
MN-60 M3rCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPqUIdKSzVyPUOuOFQxQTJizszN MlrOV2FPT0WU
SW982 MnXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzVRldyUUN3ME2zMlUxQDR6IN88US=> NHrqV2NUSU6JRWK=
RKO NUHMS3NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTzPYY5UUN3ME2zMlU{QTN4IN88US=> NHfWPY5USU6JRWK=
D-283MED NXnxNWVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHWfYMyUUN3ME2zMlU4QTh4IN88US=> M33ueHNCVkeHUh?=
LB996-RCC NE\HOYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLRTWM2OD1|Lk[yOVU5KM7:TR?= MoLhV2FPT0WU
A549 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLqTWM2OD1|Lk[zOVUzKM7:TR?= NETyT5JUSU6JRWK=
LB2241-RCC Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTNwNkW3NFgh|ryP NVvkSpc3W0GQR1XS
SK-HEP-1 NGLyO5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTNwN{SyPVch|ryP NWnTO5ZrW0GQR1XS
G-402 NWjvcG5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;u[o1KSzVyPUOuPFA5OzJizszN M3XzXHNCVkeHUh?=
GOTO MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\YTWM2OD1|Lki0N|M{KM7:TR?= NEjx[3FUSU6JRWK=
LOXIMVI M3;ROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG1VohKSzVyPUOuPFU3PzVizszN Mmq5V2FPT0WU
NH-12 M3nxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP2WWM{UUN3ME20MlAyQTV7IN88US=> M4TkWnNCVkeHUh?=
CTV-1 Ml\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrjNJpLUUN3ME20MlA4QTd|IN88US=> NEPJVYdUSU6JRWK=
CP50-MEL-B MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ewXWlEPTB;ND6yOFM6OiEQvF2= NVLlcYpRW0GQR1XS
RH-18 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIe1TXFKSzVyPUSuNlc4ODZizszN MlH4V2FPT0WU
NB17 MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fw[GlEPTB;ND6zNVc3QCEQvF2= M1fW[XNCVkeHUh?=
A375 MojvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDCT3lpUUN3ME20MlM{PTJ2IN88US=> M{j6bHNCVkeHUh?=
IST-MES1 M2Xqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvLS|JKSzVyPUSuOFE1OTFizszN NVjQdYM6W0GQR1XS
MZ2-MEL NVHTcVVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[3cpZ1UUN3ME20MlUxOTV3IN88US=> MXnTRW5ITVJ?
CAL-54 NE\EPGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLae29{UUN3ME20MlU{ODF7IN88US=> Moe0V2FPT0WU
NCI-H28 NIXTUYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnvTWM2OD12Lk[yO|E4KM7:TR?= NF3QXphUSU6JRWK=
D-247MG MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLlcVQzUUN3ME20Mlc2ODd{IN88US=> M2TwUHNCVkeHUh?=
NCI-H460 MnvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnxc4N4UUN3ME20MlkyOTJ5IN88US=> NGTaWnBUSU6JRWK=
MCF7 M1ja[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvUXW1IUUN3ME21MlQ1OjR2IN88US=> MX3TRW5ITVJ?
697 M2PtN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDBTWM2OD13LkS0OVUh|ryP NXi0OItIW0GQR1XS
ONS-76 NYnnZlNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnNXGx[UUN3ME21MlU4ODB7IN88US=> MWjTRW5ITVJ?
C32 M3vZfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPMVW1nUUN3ME21MlYxODJ7IN88US=> MmexV2FPT0WU
OS-RC-2 M3fKVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTVwN{O4PFch|ryP Mm\mV2FPT0WU
MEL-HO NWH3Zo1{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33ad2lEPTB;NT64OVY3PyEQvF2= NWLpcpdEW0GQR1XS
LoVo NF6zboJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjTTWM2OD14LkCxOlI1KM7:TR?= MUHTRW5ITVJ?
AGS Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjkU4NzUUN3ME22MlE1QDJ6IN88US=> NWnOVZF5W0GQR1XS
GI-ME-N MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fLe2lEPTB;Nj6yNlQzOSEQvF2= NVH4VYZVW0GQR1XS
H-EMC-SS NHXqV5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT1TWM2OD14LkO4OkDPxE1? MlT4V2FPT0WU
RVH-421 NFHLdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PNPGlEPTB;Nj60NlQzQCEQvF2= NEHRcHlUSU6JRWK=
SW954 NWjMOlB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTuTWM2OD14LkW1OVczKM7:TR?= MV7TRW5ITVJ?
NB5 Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;ndGlEPTB;Nj61OlE5OyEQvF2= MnTIV2FPT0WU
NCI-H2122 NGnTOZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\TTWM2OD14LkW4O|k{KM7:TR?= MWrTRW5ITVJ?
AM-38 M4LjbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzqOI84UUN3ME22Mlc2PjN7IN88US=> M3Hk[3NCVkeHUh?=
KNS-81-FD NXe1OnZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HIZmlEPTB;Nj63OlQ6PCEQvF2= MnjjV2FPT0WU
LS-513 MoXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTZwN{mwNlYh|ryP MXjTRW5ITVJ?
A427 M3P4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLQZo44UUN3ME22Mlg4QDJ7IN88US=> MljCV2FPT0WU
WM-115 NHn1ZodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTZwOUOyN{DPxE1? NG\GTlhUSU6JRWK=
COLO-829 M{jyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTdwMkSxPFgh|ryP NFrjZ|NUSU6JRWK=
NCI-H1650 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLQflh3UUN3ME23MlM6OjJ6IN88US=> Mo\0V2FPT0WU
NCI-H358 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTdwNES4O|kh|ryP MYHTRW5ITVJ?
HT-1080 NV;2elJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3Zfm1YUUN3ME23MlQ5OjV2IN88US=> Mkf5V2FPT0WU
HCC2218 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D4UmlEPTB;Nz62Nlk4KM7:TR?= NHW4V2lUSU6JRWK=
NCI-H661 NUi1fHE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MluwTWM2OD15Lki3NFY6KM7:TR?= NYro[HpKW0GQR1XS
KM-H2 M{TzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnjVo9ZUUN3ME23Mlg5Pjl2IN88US=> MUDTRW5ITVJ?
RPMI-2650 M4nnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4n4O2lEPTB;Nz65OFQyPCEQvF2= NWf5[WI3W0GQR1XS
NCI-H226 NE\zemtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z4SmlEPTB;OD6yNVEzOiEQvF2= NWj6bXQxW0GQR1XS
MKN45 NXPmelFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3qeWJiUUN3ME24MlI3PjB{IN88US=> MXfTRW5ITVJ?
D-392MG MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXO1eWx2UUN3ME24MlUzPzJ{IN88US=> NI[1[WpUSU6JRWK=
RCC10RGB NFzmR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vT[GlEPTB;OD64OlY6PSEQvF2= MkPsV2FPT0WU
CAL-51 MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\oTWM2OD17LkGwNlUyKM7:TR?= MYLTRW5ITVJ?
COLO-678 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnyxTWM2OD17LkOyPFEyKM7:TR?= MnzpV2FPT0WU
SK-MEL-24 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYn6fY9WUUN3ME25MlU2QDV4IN88US=> M4HtfHNCVkeHUh?=
SK-MEL-30 NYTycnJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfYTWM2OD17Lkm0OFc3KM7:TR?= NYfPdGpkW0GQR1XS
MMAC-SF MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle2TWM2OD1zMD6zPVYyKM7:TR?= Mm\sV2FPT0WU
NTERA-S-cl-D1 MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Qe2lEPTB;MUCuOlUxQCEQvF2= MnXLV2FPT0WU
NB12 NX3nNXhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrtT2gxUUN3ME2xNU42ODNizszN NF\5fJNUSU6JRWK=
UACC-257 NXrEUJY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnkTWM2OD1zMT64Olk2KM7:TR?= MXfTRW5ITVJ?
LAN-6 M3PBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7JV4dKSzVyPUGxMlk6OjhizszN NFj4WJZUSU6JRWK=
SW1573 MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF{LkOwPFYh|ryP NYLNcWNJW0GQR1XS
NMC-G1 M{G1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{m3NGlEPTB;MUKuOFE4PSEQvF2= MmT5V2FPT0WU
SHP-77 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjhPXpJUUN3ME2xNk42PTd2IN88US=> NWXGZZhWW0GQR1XS
IGROV-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO2WHdxUUN3ME2xNk43PTd|IN88US=> NU\EfnVjW0GQR1XS
22RV1 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnJOXpPUUN3ME2xNk45ODV7IN88US=> NX[1NW1SW0GQR1XS
SK-MEL-3 M3zRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWxZmpHUUN3ME2xN{4{QTd|IN88US=> M{DD[HNCVkeHUh?=
NCI-H1563 M2HFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPzUJhbUUN3ME2xN{41OjB{IN88US=> NF:ycWNUSU6JRWK=
IGR-1 M2PseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXyVnVKSzVyPUG0MlA{PDdizszN MkP5V2FPT0WU
EW-3 NIPZe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf0TWM2OD1zND6xOlM6KM7:TR?= MVjTRW5ITVJ?
JEG-3 NVW4[I9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHUSWpKSzVyPUG0MlQ6PTNizszN M3LiTHNCVkeHUh?=
ES3 MkDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjxTWM2OD1zND62OVYzKM7:TR?= NGqzZmpUSU6JRWK=
MDA-MB-175-VII MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;tZ4JMUUN3ME2xOE44OTFzIN88US=> MYrTRW5ITVJ?
P30-OHK NUTu[pF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zGcGlEPTB;MUWuNFQ6PiEQvF2= NIjOSXNUSU6JRWK=
GP5d NGjmbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HVUmlEPTB;MUWuNVQ3PiEQvF2= NF3VNohUSU6JRWK=
HMV-II M3LNdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF3LkOzN|Mh|ryP M3XEfHNCVkeHUh?=
COLO-679 M3HPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfYfI5KSzVyPUG1MlUxOSEQvF2= NG[3cVNUSU6JRWK=
JAR NGnOWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojOTWM2OD1zNT63NlA2KM7:TR?= MXHTRW5ITVJ?
NCI-H1666 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnGepVwUUN3ME2xOU46Ozl7IN88US=> NGPOZlJUSU6JRWK=
SW48 NILxWHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmr2TWM2OD1zNT65OVE3KM7:TR?= M4[0bXNCVkeHUh?=
NCI-H720 NGnle3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml75TWM2OD1zNT65PVg6KM7:TR?= MnHNV2FPT0WU
HT-1197 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmwWYRyUUN3ME2xOk4xOzV{IN88US=> NHTtb2RUSU6JRWK=
HL-60 MnG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzETWM2OD1zNj6wN|g1KM7:TR?= M3;mdXNCVkeHUh?=
BEN M{HZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3jOG1xUUN3ME2xOk42PjN6IN88US=> NVzWOJc5W0GQR1XS
HAL-01 NWDBe4lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDtNnJKSzVyPUG2Mlg6ODlizszN NVv6ZmpFW0GQR1XS
SW900 MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF4LkmxN|Ih|ryP MUjTRW5ITVJ?
SBC-1 M1nyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjncJVMUUN3ME2xO{42PDJ7IN88US=> M2n2[XNCVkeHUh?=
SH-4 NHfO[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzTTWM2OD1zNz61PFQyKM7:TR?= NGf1eGVUSU6JRWK=
UACC-62 MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPaTWM2OD1zNz63OlM4KM7:TR?= MULTRW5ITVJ?
BHT-101 MnnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y5SWlEPTB;MUmuPFcxPSEQvF2= MmPLV2FPT0WU
DB M4L5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTVUJhxUUN3ME2yNU42PjR7IN88US=> M4r4S3NCVkeHUh?=
SK-MEL-1 NUTHdItnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3f5TWlEPTB;MkGuOVg4OiEQvF2= Ml2yV2FPT0WU
NCI-H747 NFvEN45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLxfWVKUUN3ME2yNk44Ozd7IN88US=> MWPTRW5ITVJ?
SK-LU-1 M2TWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDBTWM2OD1{Mz6zOVI1KM7:TR?= MYfTRW5ITVJ?
KG-1 NU[4enZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJ|LkS5OFYh|ryP MnTEV2FPT0WU
LXF-289 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ThU2lEPTB;MkOuO|E1KM7:TR?= NHW3eGlUSU6JRWK=
HCC1954 Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTJ2Lki4OFQh|ryP MnLWV2FPT0WU
Ramos-2G6-4C10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\2WIVKSzVyPUK2MlQ6QDFizszN M4[zWXNCVkeHUh?=
DBTRG-05MG NWnVVZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf4TWM2OD1{Nj62OFg5KM7:TR?= M3zwUHNCVkeHUh?=
NCI-H2052 M4HTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3De2xFUUN3ME2yO{42Pjh2IN88US=> M1mxTXNCVkeHUh?=
RMG-I MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ7LkSxN|kh|ryP NH;5eoVUSU6JRWK=
H9 NUDVR3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXK4VXFJUUN3ME2zNU4{ODB6IN88US=> MY\TRW5ITVJ?
GR-ST NHvpTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTN{LkS0OVMh|ryP MnrkV2FPT0WU
Mo-T Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml22TWM2OD1|Mj61NFQ3KM7:TR?= NELKOXhUSU6JRWK=
SW1088 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\YbnRHUUN3ME2zNk46QDBzIN88US=> M3rJc3NCVkeHUh?=
LB2518-MEL NV\RZoc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTN|LkC3PVch|ryP MW\TRW5ITVJ?
NCI-H82 NED3Z4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDjXnVKSzVyPUOzMlE3PjFizszN NEHseW5USU6JRWK=
LAMA-84 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TzfGlEPTB;M{SuOlA4OyEQvF2= NXrlfZdDW0GQR1XS
KYSE-450 NV3ycZVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PifWlEPTB;M{SuOlc4PiEQvF2= Mmn5V2FPT0WU
LU-99A NWTJUXhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfGcIJKSzVyPUO1MlAxODdizszN NV[2RYFMW0GQR1XS
BE-13 M1zqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTN3Lk[1OFUh|ryP M1e0cnNCVkeHUh?=
GAK NGW0Sm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\RVmlEPTB;M{WuOlk2KM7:TR?= M3\qRnNCVkeHUh?=
NCI-H1573 NWW1XGVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrnXYg2UUN3ME2zOU45QDF6IN88US=> M3fHW3NCVkeHUh?=
AsPC-1 NH;5TWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTqTWM2OD1|Nj6xOVI4KM7:TR?= NYjidoVNW0GQR1XS
HDLM-2 NX;R[ZczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moe1TWM2OD1|Nj6zNVYh|ryP MmPXV2FPT0WU
NCI-H441 MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPYOopKSzVyPUO3MlA3QTFizszN MVTTRW5ITVJ?
CAL-27 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m1VGlEPTB;M{euO|I{OSEQvF2= MmnMV2FPT0WU
OVCAR-3 NIj6SlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jZNWlEPTB;M{muN|E5OSEQvF2= NVmydIFSW0GQR1XS
RPMI-8226 NWrIbo9{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\xTWM2OD1|OT61PVgh|ryP MnmyV2FPT0WU
EFO-21 NWi0fld7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnSTWM2OD12MD61PFE1KM7:TR?= NFPVW4JUSU6JRWK=
SNU-C2B NH\UOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH4TWM2OD12MT61NFg1KM7:TR?= M1LCU3NCVkeHUh?=
VM-CUB-1 M1fsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHTeoVKSzVyPUSzMlgxOzdizszN NXjRVJdQW0GQR1XS
NCI-H2087 NYf6UFlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL6UXZiUUN3ME20OU4xOjN|IN88US=> MVHTRW5ITVJ?
EW-16 MnrPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXKTWM2OD12Nj6zNVM4KM7:TR?= MXHTRW5ITVJ?
SK-N-AS NUXVeYhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37EVGlEPTB;NE[uO|E3PyEQvF2= NImyeohUSU6JRWK=
COR-L105 NHXzfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHQRWdKSzVyPUS2Mlg5PTdizszN NHHrbVhUSU6JRWK=
DEL NHrWT3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7tXno5UUN3ME20PE4xPDJ7IN88US=> MYTTRW5ITVJ?
JVM-2 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTR6LkC1OVgh|ryP M{fmOnNCVkeHUh?=
KARPAS-45 NEXOW25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XIcmlEPTB;NEmuOFU{QCEQvF2= MXLTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. Nutlin-3 is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with Nutlin-3a.

Protocol

Kinase Assay:[3]
+ Expand

Biacore studies:

Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of inhibitor is calculated as a percentage of binding in the absence of inhibitor and IC50 is calculated using Microsoft Excel
Cell Research:[2]
+ Expand
  • Cell lines: OSA, T778, RMS13, U2OS, SaOS-2
  • Concentrations: ~5 μM
  • Incubation Time: 120 h
  • Method: SRB
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: SJSA-1 xenograft
  • Formulation: 1% Klucel, 0.1% Tween 80
  • Dosages: 50, 100, 200 mg/kg twice daily
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water <1 mg/mL
In vivo 5% DMSO+55% PEG 300+ddH2O 8mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.49
Formula

C30H30Cl2N4O4

CAS No. 675576-98-4
Storage powder
in solvent
Synonyms (-)-Nutlin-3

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3a | Nutlin-3a supplier | purchase Nutlin-3a | Nutlin-3a cost | Nutlin-3a manufacturer | order Nutlin-3a | Nutlin-3a distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID